Elamin H Elbasha

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
  2. ncbi request reprint Deadweight loss of bacterial resistance due to overtreatment
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, Atlanta 30341, USA
    Health Econ 12:125-38. 2003
  3. ncbi request reprint Global stability of equilibria in a two-sex HPV vaccination model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, P O Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:894-909. 2008
  4. doi request reprint Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
  5. ncbi request reprint Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 13:21-35. 2004
  6. doi request reprint Characterizing Heterogeneity Bias in Cohort-Based Models
    Elamin H Elbasha
    Health Economic Statistics, Merck Research Laboratories, Merck and Co Inc, UG1C 60, PO Box 1000, North Wales, PA, 19454 1099, USA
    Pharmacoeconomics 33:857-65. 2015
  7. doi request reprint Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
    Elamin H Elbasha
    Merck and Co Inc, Kenilworth, NJ, USA
    Pharmacoeconomics 34:13-22. 2016
  8. doi request reprint Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods
    Elamin H Elbasha
    Merck and Co, Inc, Kenilworth, NJ EHE and Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston TX JC
    Med Decis Making 36:115-31. 2016
  9. doi request reprint Model for hepatitis C virus transmissions
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, United States
    Math Biosci Eng 10:1045-65. 2013
  10. doi request reprint Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elamin H Elbasha
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Appl Health Econ Health Policy 11:65-78. 2013

Detail Information

Publications30

  1. pmc Model for assessing human papillomavirus vaccination strategies
    Elamin H Elbasha
    Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Emerg Infect Dis 13:28-41. 2007
    ..The ICER of this strategy was $45,056 per QALY...
  2. ncbi request reprint Deadweight loss of bacterial resistance due to overtreatment
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, Atlanta 30341, USA
    Health Econ 12:125-38. 2003
    ..The annual deadweight loss associated with outpatient prescriptions for amoxicillin in the United States is estimated at US dollars 225 million...
  3. ncbi request reprint Global stability of equilibria in a two-sex HPV vaccination model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, P O Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:894-909. 2008
    ..If the effective reproduction number is less than unity, the infection-free equilibrium is globally asymptotically stable, and HPV will be eliminated...
  4. doi request reprint Structural differences among cost-effectiveness models of human papillomavirus vaccines
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Expert Rev Vaccines 7:895-913. 2008
    ....
  5. ncbi request reprint Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 13:21-35. 2004
    ..We derive the optimal decision rules under variable returns to scale using optimization techniques, and employ several examples to illustrate the concepts and methods...
  6. doi request reprint Characterizing Heterogeneity Bias in Cohort-Based Models
    Elamin H Elbasha
    Health Economic Statistics, Merck Research Laboratories, Merck and Co Inc, UG1C 60, PO Box 1000, North Wales, PA, 19454 1099, USA
    Pharmacoeconomics 33:857-65. 2015
    ..However, the direction of the bias is not known a priori. We characterized mathematically the conditions that lead to upward or downward bias...
  7. doi request reprint Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
    Elamin H Elbasha
    Merck and Co Inc, Kenilworth, NJ, USA
    Pharmacoeconomics 34:13-22. 2016
    ..We also demonstrate that both the trapezoidal and Simpson's rules can easily be implemented in commonly used software. ..
  8. doi request reprint Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods
    Elamin H Elbasha
    Merck and Co, Inc, Kenilworth, NJ EHE and Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston TX JC
    Med Decis Making 36:115-31. 2016
    ..The objective was to provide theoretical foundations for HCC and to compare (both mathematically and numerically) the performance of different correction methods in reducing errors in outcomes from DTSTMs...
  9. doi request reprint Model for hepatitis C virus transmissions
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, United States
    Math Biosci Eng 10:1045-65. 2013
    ..Further, treatment regimens with better efficacy holds great promise for lowering the public health burden of HCV disease. ..
  10. doi request reprint Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal
    Elamin H Elbasha
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, USA
    Appl Health Econ Health Policy 11:65-78. 2013
    ..The recent approval of two protease inhibitors, boceprevir and telaprevir, is likely to change the management of chronic hepatitis C virus (HCV) genotype 1 infection...
  11. doi request reprint Age-based programs for vaccination against HPV
    Elamin H Elbasha
    Merck Research Laboratories, Merck and Co, Inc, NorthWales, PA, USA
    Value Health 12:697-707. 2009
    ..Answering the question of which age groups are appropriate to target for catch-up vaccination with the newly licensed quadrivalent HPV vaccine (types 6/11/16/18) will be important for developing vaccine policy recommendations...
  12. doi request reprint A multi-type HPV transmission model
    Elamin H Elbasha
    Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Bull Math Biol 70:2126-76. 2008
    ....
  13. ncbi request reprint Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach
    Elamin H Elbasha
    US Centers for Disease Control and Prevention, USA
    Health Econ 14:457-70. 2005
    ..An empirical example to illustrate the methods and concepts is provided...
  14. ncbi request reprint Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, USA
    Bull Math Biol 68:577-614. 2006
    ....
  15. ncbi request reprint Vaccination against multiple HPV types
    Elamin H Elbasha
    Merck Research Laboratories, 10 Sentry Parkway, BL 2 3, Blue Bell, PA 19422, United States
    Math Biosci 197:88-117. 2005
    ..We show that if interactions among HPV types are synergistic, mass vaccination may reduce the prevalence of types that are not even included in the vaccine...
  16. ncbi request reprint Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation
    Ralph P Insinga
    Department of Health Economic Statistics UG1C 60, Merck Research Laboratories, PO Box 1000, North Wales, PA 19454 1099, USA
    Vaccine 26:128-39. 2007
    ..S.) per quality-adjusted life year (QALY) gained for female vaccination strategies to approximately 16000 dollars /QALY for adding male vaccination with catch-up...
  17. pmc Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States
    Jagpreet Chhatwal
    Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA Merck, Sharp, and Dohme Corp, Whitehouse Station, NJ, USA Electronic address
    Value Health 16:973-86. 2013
    ..We evaluated the cost-effectiveness of treatment with BOC in previously treated patients with chronic hepatitis C in the United States using treatment-related data from RESPOND-2 and PROVIDE studies...
  18. ncbi request reprint Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease
    Erik J Dasbach
    Merck Research Laboratories, Blue Bell, PA, USA
    Epidemiol Rev 28:88-100. 2006
    ....
  19. doi request reprint Impact of vaccinating boys and men against HPV in the United States
    Elamin H Elbasha
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, Merck and Co, Inc, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA elamin
    Vaccine 28:6858-67. 2010
    ..Vaccinating boys and men age 9-26 against all HPV 6/11/16/18-associated diseases provides substantial public health benefits and is cost-effective at commonly cited thresholds...
  20. ncbi request reprint The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Asian Pac J Cancer Prev 9:459-66. 2008
    ....
  21. pmc Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA
    BMC Infect Dis 9:119. 2009
    ..S. population context; (2) Identify areas where additional studies are particularly needed...
  22. ncbi request reprint Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cancer Epidemiol Biomarkers Prev 16:709-15. 2007
    ..To estimate the incidence and duration of cervical human papillomavirus (HPV)-6, HPV-11, HPV-16, and HPV-18 infections in a population of young American women...
  23. doi request reprint Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women
    Ralph P Insinga
    Merck Research Laboratories, North Wales, PA 19454 10099, USA
    Cancer Epidemiol Biomarkers Prev 19:1585-94. 2010
    ..We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection...
  24. doi request reprint The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, North Wales, PA 19454 1099, USA
    J Med Econ 13:110-8. 2010
    ....
  25. ncbi request reprint Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA 19422, USA
    Pharmacoeconomics 23:1107-22. 2005
    ....
  26. ncbi request reprint Preferences and person trade-offs: forcing consistency or inconsistency in health-related quality of life measures?
    Edward C Mansley
    Us centers for Disease Control and Prevention CDC, USA
    Health Econ 12:187-98. 2003
    ..We then discuss preference characterizations in the existing person trade-off literature, from which this relationship may have been derived...
  27. ncbi request reprint The decision to conduct a head-to-head comparative trial: a game-theoretic analysis
    Edward C Mansley
    Outcomes Research and Management, Merck and Co Inc, WP39 166, P O Box 4, West Point, PA 19486 000, USA
    Med Decis Making 27:364-79. 2007
    ..Finally, the results indicate that incentives that offset the direct cost of a trial can prevent a no-trial equilibrium, even when both firms face the possibility of an inferior outcome...
  28. doi request reprint Cost-effectiveness of raltegravir in HIV/AIDS
    Mohammad Ashraf Chaudhary
    Merck and Co, Inc, UG1C 60, 351 N Sumneytown Pike, PO Box 1000, North Wales, PA 19454 2505, USA
    Expert Rev Pharmacoecon Outcomes Res 11:627-39. 2011
    ..Nonetheless, raltegravir remained cost effective under most scenarios...
  29. ncbi request reprint Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
    Erik J Dasbach
    Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, UG1C 60, PO Box 1000, North Wales, PA 19454 1099, USA
    Expert Rev Pharmacoecon Outcomes Res 8:491-500. 2008
    ....
  30. ncbi request reprint Vaccination and the evolutionary ecology of human papillomavirus
    Eric M Poolman
    Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520 8034, USA
    Vaccine 26:C25-30. 2008
    ..If natural infection provides greater cross-immunity than vaccination, vaccination may expand available niche space up to 470-fold. The balance of epidemiologic data suggests vaccination will reduce the available niche space...